DE Piccioni, CM Duma, RV LaRocca, R. Aiken, TH Taylor, JA Carrillo, GI Nistor, HS Keirstead, Robert O. Dillman, DA Bota, Robert O. Dillman
{"title":"在新诊断的胶质母细胞瘤患者中，个人树突状细胞疫苗的2期试验提高了无进展生存期","authors":"DE Piccioni, CM Duma, RV LaRocca, R. Aiken, TH Taylor, JA Carrillo, GI Nistor, HS Keirstead, Robert O. Dillman, DA Bota, Robert O. Dillman","doi":"10.29011/2574-710x.010149","DOIUrl":null,"url":null,"abstract":"Standard therapy of aggressive glioblastoma (GBM), which includes maximum safe surgical resection and concurrent radiation/temozolomide (RT/TMZ) followed by maintenance TMZ, is associated with poor progression-free survival (PFS) and overall","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"49 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Enhanced Progression-Free Survival in a Phase 2 Trial of Personal Dendritic Cell Vaccines in Patients with Newly Diagnosed Glioblastoma\",\"authors\":\"DE Piccioni, CM Duma, RV LaRocca, R. Aiken, TH Taylor, JA Carrillo, GI Nistor, HS Keirstead, Robert O. Dillman, DA Bota, Robert O. Dillman\",\"doi\":\"10.29011/2574-710x.010149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Standard therapy of aggressive glioblastoma (GBM), which includes maximum safe surgical resection and concurrent radiation/temozolomide (RT/TMZ) followed by maintenance TMZ, is associated with poor progression-free survival (PFS) and overall\",\"PeriodicalId\":73876,\"journal\":{\"name\":\"Journal of oncology research and therapy\",\"volume\":\"49 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of oncology research and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29011/2574-710x.010149\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of oncology research and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29011/2574-710x.010149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Enhanced Progression-Free Survival in a Phase 2 Trial of Personal Dendritic Cell Vaccines in Patients with Newly Diagnosed Glioblastoma
Standard therapy of aggressive glioblastoma (GBM), which includes maximum safe surgical resection and concurrent radiation/temozolomide (RT/TMZ) followed by maintenance TMZ, is associated with poor progression-free survival (PFS) and overall
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
